Search for a doctor

John H. Strickler, M.D.

  1. Oncologist
Request an Appointment

Publications

  1. Reason EH, Aiduk MD, Nash AL, McDuff SGR, Renner D, Kollipara RK, Satta S, Velichko S, Kalashnikova E, Rodriguez AA, Liu MC, Strickler JH, Grilley-Olson JE, Rosenberger LH. Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study. Ann Surg Oncol. 2025 Oct; 32 (11):8299-8308 Epub 2025 July 23
    View PubMed
  2. Liu A, Reason EH, Sullivan BG, Wildman-Tobriner B, Strickler JH, Hsu SD, Hill SS, Thacker JKM, Mantyh CR, Lan B, Nussbaum D, Zani S, Allen PJ, Uronis H, Lidsky ME. Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion. Ann Surg Oncol. 2025 Oct; 32 (10):7131-7140 Epub 2025 July 09
    View PubMed
  3. Inoue K, Nakamura Y, Caughey B, Zheng-Lin B, Ueno M, Furukawa M, Kawamoto Y, Itoh S, Umemoto K, Sudo K, Satoh T, Mizuno N, Kajiwara T, Fujisawa T, Bando H, Yoshino T, Strickler JH, Morizane C, Bekaii-Saab T, Ikeda M. Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer. JCO Precis Oncol. 2025 Apr; 9:e2400718. Epub 2025 Apr 10.
    View PubMed
  4. Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21 (3):303-311 Epub 2024 Dec 26
    View PubMed
  5. Liu A, Lowe M, Niedzwiecki D, Rhodin KE, Sharib J, Wildman-Tobriner B, Wong TZ, Kim CY, Thacker J, Mantyh C, Migaly J, Lan BY, Strickler JH, David Hsu S, Nussbaum D, Zani S, Uronis H, Allen PJ, Lidsky ME. Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program. Ann Surg Oncol. 2025 Feb; 32 (2):1033-1042 Epub 2024 Nov 20
    View PubMed
  6. Kumar A, Owen JR, Sloat NT, Maynard E, Hill VM, Hubbard CB, McKinney MS, Sutton LM, McCall SJ, Datto MB, Moyer AN, Caughey BA, Strickler JH, Ramaker RC. Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States. Curr Oncol. 2024 Nov 16; 31 (11):7244-7257
    View PubMed
  7. Meernik C, Wang F, Raveendran Y, Green MF, Check DK, Bosworth HB, Sutton LM, Strickler JH, Akinyemiju TF. Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina. Cancer Res Commun. 2024 Nov 1; 4 (11):2968-2975
    View PubMed
  8. Lin C, Zhou KI, Green MF, Caughey BA, Strickler JH, Datto MB, McKinney MS. Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice. Hematol Rep. 2024 Sep 30; 16 (4):603-611 Epub 2024 Sept 30
    View PubMed
  9. Zouein J, Karam E, Strickler JH, Kourie HR. Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker. Target Oncol. 2024 Sep; 19 (5):705-710 Epub 2024 July 04
    View PubMed
  10. Meernik C, Raveendran Y, Kolarova M, Rahman F, Olunuga E, Hammond E, Shivaramakrishnan A, Hendren S, Bosworth HB, Check DK, Green M, Strickler JH, Akinyemiju T. Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review. J Natl Cancer Inst. 2024 Jun 7; 116 (6):812-828
    View PubMed
  11. Zhou KI, Hanks BA, Strickler JH. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma. J Gastrointest Cancer. 2024 Jun; 55 (2):483-496 Epub 2023 Dec 22
    View PubMed
  12. Caughey BA, Strickler JH. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Drugs. 2024 Jan; 84 (1):27-44 Epub 2023 Dec 18
    View PubMed
  13. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30 (1):265-270 Epub 2024 Jan 04
    View PubMed
  14. Strickler JH, Yoshino T, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, Modest DP. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. Oncologist. 2023 Nov 2; 28 (11):e981-e994
    View PubMed
  15. Caughey BA, Umemoto K, Green MF, Ikeda M, Lowe ME, Ueno M, Niedzwiecki D, Taniguchi H, Walden DJ, Komatsu Y, D'Anna R, Esaki T, Denda T, Datto MB, Bando H, Bekaii-Saab T, Yoshino T, Strickler JH, Nakamura Y. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas. J Gastrointest Oncol. 2023 Oct 31; 14(5):2083-2096. Epub 2023 Sep 19.
    View PubMed
  16. Bekaii-Saab TS, Lach K, Hsu LI, Siadak M, Stecher M, Ward J, Beckerman R, Strickler JH. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. Oncologist. 2023 Oct 03; 28(10):885-893.
    View PubMed
  17. Zaidi MY, Nussbaum DP, Hsu SD, Strickler JH, Uronis HE, Zani S Jr, Allen PJ, Lidsky ME. Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion. Surgery. 2023 Aug; 174 (2):428-430 Epub 2023 May 12
    View PubMed
  18. Strickler JH, Hsu LI, Wright P, Stecher M, Siadak MF, Palanca-Wessels MC, Yu J, Zhang N, Espenschied CR, Lang K, Bekaii-Saab TS. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. J Natl Compr Canc Netw. 2023 Aug; 21(8):805-812.e1.
    View PubMed
  19. Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023 Jul; 72 (7):2443-2458 Epub 2023 Apr 05
    View PubMed
  20. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS, MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May; 24(5):496-508.
    View PubMed
  21. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Feb 10; 41 (5):1105-1115 Epub 2022 Oct 26
    View PubMed
  22. Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023 Jan 20; 41 (3):678-700 Epub 2022 Oct 17
    View PubMed
  23. Green MF, Watson CH, Tait S, He J, Pavlick DC, Frampton G, Riedel J, Plichta JK, Armstrong AJ, Previs RA, Kauff N, Strickler JH, Datto MB, Berchuck A, Menendez CS. Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board. Oncologist. 2023 Jan 18; 28 (1):33-39
    View PubMed
  24. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023 Jan 5; 388 (1):33-43 Epub 2022 Dec 21
    View PubMed
  25. Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5 (1):vdac183 Epub 2022 Dec 21
    View PubMed
  26. Kumar A, Green M, Thacker J, Jeck WR, Strickler JH. Circulating Tumor DNA Testing Overcomes Limitations of Comprehensive Genomic Profiling from Tumor Tissue. Case Rep Oncol. 2023 Jan-Dec; 16 (1):210-217 Epub 2023 Apr 12
    View PubMed
  27. Sharib JM, Creasy JM, Wildman-Tobriner B, Kim C, Uronis H, Hsu SD, Strickler JH, Gholami S, Cavnar M, Merkow RP, Kingham P, Kemeny N, Zani S Jr, Jarnagin WR, Allen PJ, D'Angelica MI, Lidsky ME. Hepatic Artery Infusion Pumps: A Surgical Toolkit for Intraoperative Decision-Making and Management of Hepatic Artery Infusion-Specific Complications. Ann Surg. 2022 Dec 1; 276 (6):943-956 Epub 2022 Mar 09
    View PubMed
  28. Strickler JH, Cubillo A, Liang JT, Matrana M, Kozloff M, Lowe T, Blaney M, Sahtout M, Naumovski L, Wainberg ZA. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18 (27):3011-3020 Epub 2022 Aug 03
    View PubMed
  29. Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. J Clin Oncol. 2022 Aug 20; 40(24):2706-2715. Epub 2022 Jun 01.
    View PubMed
  30. Madan A, Uronis HE, Strickler JH. A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer. J Gastrointest Oncol. 2022 Aug; 13 (4):2007-2019
    View PubMed
  31. Strickler JH, Yoshino T, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. JAMA Oncol. 2022 May 01; 8(5):760-769.
    View PubMed
  32. Jia J, Howard L, Liu Y, Starr MD, Brady JC, Niedzwiecki D, Strickler JH, Nixon AB. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemother Pharmacol. 2022 Mar; 89 (3):413-422 Epub 2022 Feb 16
    View PubMed
  33. Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar 1; 28 (5):882-892
    View PubMed
  34. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022 Jan; 23 (1):115-124 Epub 2021 Dec 15
    View PubMed
  35. Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF, Strickler JH. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther. 2021 Nov; 20 (11):2240-2249 Epub 2021 Sept 04
    View PubMed
  36. Kao C, Powers E, Wu Y, Datto MB, Green MF, Strickler JH, Ready NE, Zhang T, Clarke JM. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021 Nov; 22 (6):500-509 Epub 2021 Mar 27
    View PubMed
  37. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 Nov 1; 27 (21):5781-5792 Epub 2021 Aug 23
    View PubMed
  38. Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park). 2021 Oct 21; 35(10):654-660.
    View PubMed
  39. Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 Oct; 20(10):1988-1995. Epub 2021 Jul 26.
    View PubMed
  40. Ciombor K, Jones J, Strickler J, Bekaii-Saab T, Wu C. The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. Oncology (Williston Park). 2021 Sep 15; 35(9):553-559.
    View PubMed
  41. Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist. 2021 Jun; 26 (6):465-e917 Epub 2021 Feb 09
    View PubMed
  42. DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, Beasley GM, Holtzhausen A, Novotny-Diermayr V, Strickler JH, Hanks BA. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021 May 4; 35 (5):109071
    View PubMed
  43. Robinson H, Green M, Radkar G, Ready N, Strickler J. Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma. Cancer Invest. 2021 Mar; 39 (3):235-239 Epub 2021 Feb 15
    View PubMed
  44. Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021 Mar 1; 27 (5):1236-1241 Epub 2020 Nov 16
    View PubMed
  45. Morris VK, Strickler JH. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annu Rev Med. 2021 Jan 27; 72:399-413
    View PubMed
  46. DeVito NC, Kelleher C, Strickland KC, Abbruzzese J, Anders C, Hanks BA, Jia J, Mettu NB, Morse MA, O'Neill M, Uronis H, Zafar Y, Strickler JH. A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. AME Case Rep. 2021; 5:14 Epub 2021 Apr 25
    View PubMed
  47. Schmitz R, Mao R, Moris D, Strickler JH, Blazer DG 3rd. Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma. Ann Surg Oncol. 2021 Jan; 28 (1):114-120 Epub 2020 June 18
    View PubMed
  48. Watson CH, Broadwater G, Wong J, Spinosa D, de Oca MKM, Datto M, Green M, Hubbard C, McKinney M, McCall SJ, Havrilesky LJ, Strickler JH, Berchuck A, Strickland KC, Previs RA. Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. Target Oncol. 2021 Jan; 16 (1):109-118 Epub 2021 Jan 05
    View PubMed
  49. Green MF, Bell JL, Hubbard CB, McCall SJ, McKinney MS, Riedel JE, Menendez CS, Abbruzzese JL, Strickler JH, Datto MB. Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. JCO Precis Oncol. 2021; 5 Epub 2021 Sept 16
    View PubMed
  50. Creasy JM, Napier KJ, Reed SA, Zani S Jr, Wong TZ, Kim CY, Wildman-Tobriner B, Strickler JH, Hsu SD, Uronis HE, Allen PJ, Lidsky ME. Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases. Ann Surg Oncol. 2020 Dec; 27 (13):5086-5095 Epub 2020 Aug 10
    View PubMed
  51. Schmitz R, Moris D, Strickler JH, Blazer DG 3rd. ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. Ann Surg Oncol. 2020 Dec; 27 (Suppl 3):804-805 Epub 2020 July 01
    View PubMed
  52. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 Dec; 17 (12):757-770 Epub 2020 July 06
    View PubMed
  53. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep 24; 383 (13):1207-1217 Epub 2020 Sept 20
    View PubMed
  54. Chen C, Di Bartolomeo M, Corallo S, Strickler JH, Goyal L. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. Am Soc Clin Oncol Educ Book. 2020 May; 40:161-173
    View PubMed
  55. Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 May; 19 (5):1210-1217 Epub 2020 Mar 03
    View PubMed
  56. Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. BMC Cancer. 2019 Nov 1; 19 (1):1032 Epub 2019 Nov 01
    View PubMed
  57. Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. 2019 Oct 1; 5 (10):1511-1512
    View PubMed
  58. Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, Nixon AB, Hurwitz HI. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemother Pharmacol. 2019 Oct; 84 (4):909-917 Epub 2019 Aug 23
    View PubMed
  59. Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019 Sep; 8 (11):5148-5157 Epub 2019 July 26
    View PubMed
  60. Turner MC, Keenan JE, Rushing CN, Gulack BC, Nussbaum DP, Benrashid E, Hyslop T, Strickler JH, Mantyh CR, Migaly J. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. J Gastrointest Surg. 2019 Aug; 23 (8):1614-1622 Epub 2019 Jan 11
    View PubMed
  61. Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer. 2019 Mar; 18(1):e117-e129. Epub 2018 Nov 16.
    View PubMed
  62. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 Feb 1; 30 (2):243-249
    View PubMed
  63. Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20; 36 (33):3298-3306 Epub 2018 Oct 04
    View PubMed
  64. Altunel E, Aljamal AA, Mantyh J, Deak K, Glover W, McCall SJ, Datto M, Strickler J, Hsu DS. Characterization of the Epidermal Growth Factor Receptor T790M Mutation in Colorectal Cancer. JCO Precis Oncol. 2018 Nov; 2:1-7
    View PubMed
  65. Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, Strickler JH. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. J Med Econ. 2018 Nov; 21 (11):1075-1083 Epub 2018 Sept 28
    View PubMed
  66. Bekaii-Saab T, Marcello K, Fisher G, Kopetz S, Strickler J, Venook A, Obholz K. Variability of current global practice patterns in the management of metastatic colorectal cancer. Ann Oncol. 2018 Jun; 29 Suppl 5:v73 Epub 2020 Jan 07
    View PubMed
  67. Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018 Apr; 118 (7):938-946 Epub 2018 Mar 12
    View PubMed
  68. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov. 2018 Feb; 8 (2):164-173 Epub 2017 Dec 01
    View PubMed
  69. Jia J, Morse MA, Nagy RJ, Lanman RB, Strickler JH. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Front Oncol. 2018; 8:305 Epub 2018 Aug 28
    View PubMed
  70. Tachibana M, Papadopoulos KP, Strickler JH, Puzanov I, Gajee R, Wang Y, Zahir H. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. Br J Clin Pharmacol. 2018 Jan; 84 (1):112-121 Epub 2017 Oct 29
    View PubMed
  71. Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov; 60:109-119. Epub 2017 Aug 31.
    View PubMed
  72. Zhu J, Strickler JH. Clinical applications of liquid biopsies in gastrointestinal oncology. J Gastrointest Oncol. 2016 Oct; 7 (5):675-686
    View PubMed
  73. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1; 34 (22):2654-68 Epub 2016 May 31
    View PubMed
  74. Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ. Development of a Novel c-MET-Based CTC Detection Platform. Mol Cancer Res. 2016 Jun; 14 (6):539-47 Epub 2016 Mar 07
    View PubMed
  75. Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM, TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2016 Jan 21; 37(4):412-22. Epub 2015 Dec 05.
    View PubMed
  76. Zhu J, Strosberg JR, Dropkin E, Strickler JH. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Cancer. 2015 Jun; 46 (2):166-9
    View PubMed
  77. Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol. 2015 Apr; 75(4):851-9. Epub 2015 Feb 27.
    View PubMed
  78. Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs. 2014 Aug; 32 (4):700-9 Epub 2014 Apr 09
    View PubMed
  79. Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs. 2014 Apr; 32 (2):330-9 Epub 2013 Nov 01
    View PubMed
  80. Nussbaum DP, Bhattacharya SD, Jiang X, Cardona DM, Strickler JH, Blazer DG 3rd. Gastroesophageal heterotopia and HER2/neu overexpression in an adenocarcinoma arising from a small bowel duplication. Arch Pathol Lab Med. 2014 Mar; 138 (3):428-31
    View PubMed
  81. Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep. 2014; 16 (1):363
    View PubMed
  82. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol. 2012 Aug; 70 (2):251-8 Epub 2012 June 29
    View PubMed
  83. Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012; 17 (4):513-24 Epub 2012 Apr 03
    View PubMed
  84. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14 (10):3156-67
    View PubMed
  85. Coil DA, Strickler JH, Rai SK, Miller AD. Jaagsiekte sheep retrovirus Env protein stabilizes retrovirus vectors against inactivation by lung surfactant, centrifugation, and freeze-thaw cycling. J Virol. 2001 Sep; 75 (18):8864-7
    View PubMed
PST-20608643